Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis

Extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis, now known to be present in 50 countries, heighten the threat posed by untreatable and fatal human tuberculosis (TB). To combat epidemics of drug-resistant TB, it is vital to understand why some resistant strains have greater reproductive fitness — a greater propensity to spread — than drug-susceptible strains. If public health malpractice has been a more important determinant of reproductive success than genetic mechanisms, then improved diagnosis and treatment could keep the frequency of resistant strains among TB cases low in any population. Recent data suggest that national TB control programmes that use existing drugs efficiently can postpone and even reverse epidemics of multidrug-resistant TB, although the effect of such programmes on XDR strains remains largely unknown.

[1]  D. Menzies,et al.  Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. , 2008, American journal of respiratory and critical care medicine.

[2]  S. Glickman,et al.  A Portfolio Model of Drug Development for Tuberculosis , 2006, Science.

[3]  J. Bayona,et al.  Management of Extensively Drug-Resistant Tuberculosis in Peru: Cure Is Possible , 2008, PloS one.

[4]  D. van Soolingen,et al.  Genotype and phenotype relationships and transmission analysis of drug-resistant tuberculosis in Singapore. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[5]  Ross Upshur,et al.  XDR-TB in South Africa: No Time for Denial or Complacency , 2007, PLoS medicine.

[6]  A. Khomenko,et al.  Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. , 2000, JAMA.

[7]  G W Comstock,et al.  Epidemiology of tuberculosis. , 1982, The American review of respiratory disease.

[8]  M. Morrow,et al.  Long term efficacy of DOTS regimens for tuberculosis: systematic review , 2008, BMJ : British Medical Journal.

[9]  M. Borgdorff,et al.  Beijing/W Genotype Mycobacterium tuberculosis and Drug Resistance , 2006, Emerging infectious diseases.

[10]  L. Tanoue Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis , 2009 .

[11]  Mehran Hosseini,et al.  Global incidence of multidrug-resistant tuberculosis. , 2006, The Journal of infectious diseases.

[12]  Fernando Baquero,et al.  Predicting antibiotic resistance , 2007, Nature Reviews Microbiology.

[13]  Yong Soo Choi,et al.  Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  C. Dye,et al.  Will tuberculosis become resistant to all antibiotics? , 2001, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[15]  C. Garzelli Beijing/W Genotype Mycobacterium tuberculosis and Drug Resistance , 2006 .

[16]  T. Chou,et al.  Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance , 2004, Nature Medicine.

[17]  M. Uplekar,et al.  WHO's new Stop TB Strategy , 2006, The Lancet.

[18]  J. Furin The clinical management of drug-resistant tuberculosis , 2007, Current opinion in pulmonary medicine.

[19]  B G Williams,et al.  Criteria for the control of drug-resistant tuberculosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Christopher Dye,et al.  Prospects for worldwide tuberculosis control under the WHO DOTS strategy , 1998, The Lancet.

[21]  J. Hansan The end of an era. , 1996, Journal of aging & social policy.

[22]  S. Niemann,et al.  The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia , 2005, Respiratory research.

[23]  C. Dye,et al.  Can DOTS control multidrug-resistant tuberculosis? , 2005, The Lancet.

[24]  K. Floyd,et al.  Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries. , 2002, Bulletin of the World Health Organization.

[25]  T. Holtz,et al.  Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study , 2005, The Lancet.

[26]  S. Gillespie,et al.  Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). , 2008, Tuberculosis.

[27]  R. Koenig In South Africa, XDR TB and HIV Prove a Deadly Combination , 2008, Science.

[28]  M. Spigelman,et al.  New tuberculosis therapeutics: a growing pipeline. , 2007, The Journal of infectious diseases.

[29]  C. Dye,et al.  Worldwide incidence of multidrug-resistant tuberculosis. , 2002, The Journal of infectious diseases.

[30]  N. Schluger,et al.  Underreported Threat of Multidrug-Resistant Tuberculosis in Africa , 2008, Emerging infectious diseases.

[31]  T. Cohen,et al.  Challenges in estimating the total burden of drug-resistant tuberculosis. , 2008, American journal of respiratory and critical care medicine.

[32]  Sonya S. Shin,et al.  Epidemiology and Treatment of Multidrug Resistant Tuberculosis , 2008, Seminars in respiratory and critical care medicine.

[33]  P. Deschavanne,et al.  Contribution of horizontally acquired genomic islands to the evolution of the tubercle bacilli. , 2007, Molecular biology and evolution.

[34]  Pradeep Mitra Ecspe,et al.  REPORT NO , 2001 .

[35]  M. Edwards Evidence , 2004, The Lancet.

[36]  P. V. van Helden,et al.  Beijing and Haarlem Genotypes Are Overrepresented among Children with Drug-Resistant Tuberculosis in the Western Cape Province of South Africa , 2006, Journal of Clinical Microbiology.

[37]  J. Yudkin,et al.  Extensively drug-resistant tuberculosis in sub-Saharan Africa: an emerging public-health concern. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[38]  D. van Soolingen,et al.  A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes , 2003, Clinical and experimental immunology.

[39]  Ted Cohen,et al.  Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness , 2004, Nature Medicine.

[40]  J. Farrar,et al.  The Influence of Host and Bacterial Genotype on the Development of Disseminated Disease with Mycobacterium tuberculosis , 2008, PLoS pathogens.

[41]  D. Andersson,et al.  Effect of rpoB Mutations Conferring Rifampin Resistance on Fitness of Mycobacterium tuberculosis , 2004, Antimicrobial Agents and Chemotherapy.

[42]  Roger Finch,et al.  Lack of development of new antimicrobial drugs: a potential serious threat to public health. , 2005, The Lancet. Infectious diseases.

[43]  D. Caugant,et al.  Impact of drug resistance on fitness of Mycobacterium tuberculosis strains of the W-Beijing genotype. , 2004, FEMS immunology and medical microbiology.

[44]  E. Nardell,et al.  Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. , 2007, The Journal of infectious diseases.

[45]  G. Bai,et al.  Worldwide Emergence of Extensively Drug-resistant Tuberculosis , 2007, Emerging infectious diseases.

[46]  S. Levy,et al.  Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.

[47]  P. V. van Helden,et al.  Spread of a Low-Fitness Drug-Resistant Mycobacterium tuberculosis Strain in a Setting of High Human Immunodeficiency Virus Prevalence , 2008, Journal of Clinical Microbiology.

[48]  Sonya S. Shin,et al.  Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study , 2008, The Lancet.

[49]  S. Schrag,et al.  Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study , 2008, The Lancet.

[50]  A. Chaiprasert,et al.  Distribution of rpoB mutations among multidrug-resistant Mycobacterium tuberculosis (MDRTB) strains from Thailand and development of a rapid method for mutation detection. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[51]  B. Cowling,et al.  Age-period-cohort analysis of tuberculosis notifications in Hong Kong , 2006 .

[52]  Neel R Gandhi,et al.  Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa , 2006, The Lancet.

[53]  Ted Cohen,et al.  The effect of drug resistance on the fitness of Mycobacterium tuberculosis. , 2003, The Lancet. Infectious diseases.

[54]  S. Blower,et al.  Predicting the future of XDR tuberculosis. , 2007, The Lancet. Infectious diseases.

[55]  C. D. Long,et al.  The Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis , 2006, Science.

[56]  M. Donald Cave,et al.  Population Genetics Study of Isoniazid Resistance Mutations and Evolution of Multidrug-Resistant Mycobacterium tuberculosis , 2006, Antimicrobial Agents and Chemotherapy.

[57]  C. Dye,et al.  The decline of tuberculosis epidemics under chemotherapy: a case study in Morocco. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[58]  Patrick Deschavanne,et al.  Horizontal transfer of a virulence operon to the ancestor of Mycobacterium tuberculosis. , 2006, Molecular biology and evolution.

[59]  A. W. Sturm,et al.  Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. , 2007, Clinical Infectious Diseases.

[60]  C. Tam,et al.  Age-period-cohort analysis of tuberculosis notifications in Hong Kong from 1961 to 2005 , 2007, Thorax.

[61]  E. Chan,et al.  Treatment outcomes in extensively resistant tuberculosis. , 2008, The New England journal of medicine.

[62]  M. Raviglione XDR-TB: entering the post-antibiotic era? , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[63]  K. Derbyshire,et al.  IS6110, a Mycobacterium tuberculosis Complex-Specific Insertion Sequence, Is Also Present in the Genome of Mycobacterium smegmatis, Suggestive of Lateral Gene Transfer among Mycobacterial Species , 2008, Journal of bacteriology.

[64]  J. Mukherjee,et al.  Multidrug-resistant Tuberculosis Management in Resource-limited Settings , 2006, Emerging infectious diseases.

[65]  C. Dye,et al.  The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. , 2001, The Journal of infectious diseases.

[66]  Stefan Niemann,et al.  Tuberculosis Recurrence and Mortality after Successful Treatment: Impact of Drug Resistance , 2006, PLoS medicine.

[67]  F. Cobelens,et al.  Scaling Up Programmatic Management of Drug-Resistant Tuberculosis: A Prioritized Research Agenda , 2008, PLoS medicine.

[68]  J. Bayona,et al.  Long-term Follow-up for Multidrug-resistant Tuberculosis , 2006, Emerging infectious diseases.

[69]  E. Nardell Environmental infection control of tuberculosis. , 2003, Seminars in respiratory infections.

[70]  S. Niemann,et al.  Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  Brian G. Williams,et al.  Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis , 2002, Science.

[72]  P. Small,et al.  Does DOTS work in populations with drug-resistant tuberculosis? , 2005, The Lancet.